Vaccination procedures against Coxsackievirus-induced heart disease

Expert Review of Vaccines

Volumn 2, Issue 6, 2003, Pages 805-815

  Henke, Andreas ^a   Jarasch, Nadine ^a   Wutzler, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Coxsackievirus; Myocarditis; Vaccination strategies

Indexed keywords

BETA INTERFERON; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC DISEASE; CONTROLLED STUDY; COXSACKIE VIRUS B3; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOUSE; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; VACCINATION; VACCINE PRODUCTION; VIRUS MYOCARDITIS; VIRUS PATHOGENESIS;

ANIMALS; CARDIOMYOPATHIES; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; HUMANS; VACCINATION; VACCINES, DNA; VIRAL VACCINES;

EID: 0348110379     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.6.805     Document Type: Review

References (78)

1. Melnick JL, Shaw EW, Curen EC. A virus isolated from patients diagnosed as nonparalytic poliomyelitis or aseptic meningitis. Proc. Soc. Exptl. Biol. Med. 71, 344-349 (1949).
2. Bergdson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323 (1997).
3. Spiller OB, Goodfellow IG, Evans DJ et al. Echoviruses and Coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF. J. Infect. Dis. 181, 340-343 (2000).
4. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B Coxsackieviruses. Proc. Natl. Acad. Sci. USA 94, 3352-3356 (1997).
5. Zautner AE, Komer U, Henke A et al. Heparan sulfates and Coxsackievirus-adenovirus receptor: each one mediates Coxsackievirus B3 PD infection. J. Virol. 77, 10071-10077 (2003).
6. Liebig HD, Ziegler E, Yan R et al. Purification of two picomaviral 2A proteinases: interaction with eIF-4 γ and influence on in vitro translation. Biochemistry 32, 7581-7588 (1993).
7. Badorff C, Lee GH, Lamphear BJ et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5, 320-326 (1999).
8. Kim KS, Hufnagel G, Claman NM, Tracy S. The group B Coxsackieviruses and myocarditis. Rev. Med. Virol. 11, 355-368 (2001).
9. Gravanis MB, Sternby NH. Incidence of myocarditis. A 10-year autopsy study from Malmo, Sweden. Arch. Pathol. Lab. Med. 115, 390-392 (1991).
10. Ramsingh AI. Coxsackieviruses and Pancreatitis. Front. Biosci. 2, E53-E62 (1997).
11. Tracy S, Hofling K, Pirruccello S et al. Group B Coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice. J. Med. Virol. 62, 70-81 (2000).
12. Hyoty H, Taytor KW. The role of viruses in human diabetes. Diabetologia 45, 1353-1361 (2002).
13. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab. Res. Rev. 19, 8-31 (2003).
14. Clavell M, Barkemeyer B, Martinez B et al. Severe hepatitis in a newborn with Coxsackievirus B5 infection. Clin. Pediatr. (Phila) 38, 739-741 (1999).
15. Gregor GR, Geller SA, Walker GF, Campomanes BA. Coxsackie hepatitis in an adult, with ultrastructural demonstration of the virus. Mt. Sinai J. Med. 42, 575-580 (1975).
16. Gauntt CJ, Sakkinen P, Rose NR, Huber SA. Picornaviruses: immunopathology and autoimmunity In: Cunningham MW and Fujinami RS (Ed.), Effects of microbes on the immune system. Lippincott-Raven, PA, USA 313-329 (1999).
17. Grist NR, Bell EJ, Assaad F. Enteroviruses in human disease. Prog. Med. Virol. 24, 114-157 (1978).
18. Woodruff JF. Viral myocarditis. A review. Am. J. Pathol. 101, 425-484 (1980).
19. Chow LH, Gauntt CJ, McManus BM. Differential effects of myocarditic variants of Coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. Lab. Invest. 64, 55-64 (1991).
20. Huber SA. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab. Invest. 76, 691-701 (1997).
21. Riecansky I, Schreinerova Z, Egnerova A et al. Incidence of Coxsackie virus infection in patients with dilated cardiomyopathy. Cor. Vasa. 31, 225-230 (1989).
22. Tam PE, Messner RP. Molecular mechanisms of Coxsackievirus persistence in chronic inflammatory myopathy: viral RNA persists through formation of a double-stranded complex without associated genomic mutations or evolution. J. Virol. 73, 10113-10121 (1999).
23. Feuer R, Mena I, Pagarigan R et al. Cell cycle status affects Coxsackievirus replication, persistence, and reactivation in vitro. J. Virol. 76, 4430-4440 (2002).
24. Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine Coxsackievirus B3 model. Antiviral and anti-inflammatory effects. Circulation 92, 1604-1611 (1995).
25. Girn J, Kavoosi M, Chantler J. Enhancement of Coxsackievirus B3 infection by antibody to a different Coxsackievirus strain. J. Gen. Virol. 83, 351-358 (2002).
26. Kearns GL, Abdel-Rahman SM, James LP et al. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Pediatric Pharmacology Research Unit Network. Antimicrob. Agents Chemother. 43, 634-638 (1999).
27. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43, 2109-2115 (1999).
28. Sawyer MH. Enterovirus infections: diagnosis and treatment. Pediatr. Infect. Dis. J. 18, 1033-1039; quiz 1040 (1999).
29. Heim A, Canu A, Kirschner P et al. Synergistic interaction of IFN-β and IFN-γ in Coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J. Infect. Dis. 166, 958-965 (1992).
30. Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha IFN on Coxsackievirus B3 myocarditis in mice. Am. Heart J. 115, 1229-1232 (1988).
31. Kuhl U, Pauschinger M, Schwimmbeck PL et al. IFN-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfuncfion. Circulation 107, 2793-2798 (2003).
32. + T lymphocytes in Coxsackievirus B3-induced myocarditis. J. Virol. 69, 6720-6728 (1995).
33. Mena I, Perry CM, Harkins S et al. The role of B lymphocytes in Coxsackievirus B3 infection. Am. J. Pathol. 155, 1205-1215 (1999).
34. Wigdorovitz A, Carrillo C, Dus Santos MJ et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 255, 347-353 (1999).
35. Godney EK, Arizpe HM, Gauntt CJ. Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis. Viral Immunol. 1, 305-314 (1987).
36. Landau BJ, Whittier PS, Finkelstein SD et al. Induction of heterotypic virus resistance in adult inbred mice immunized with a variant of Coxsackievirus B3. Microb. Pathog. 8, 289-298 (1990).
37. Zhang H, Morgan-Capner P, Latif N et al. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Am. J. Pathol. 150, 2197-2207 (1997).
38. Cameron-Wilson CL, Pandolfino YA, Zhang HY et al. Nucleotide sequence of an attenuated mutant of Coxsackievirus B3 compared with the cardiovirulent wildtype: assessment of candidate mutations by anaxlysis of a revertant to cardiovirulence. Clin. Diagn. Virol. 9, 99-105 (1998).
39. Tracy S, Tu Z, Chapman N, Hufiiagel G. Genetics of Coxsackievirus B3 cardiovirulence. Eur. Heart J. 16(Suppl.), 15-17 (1995).
40. Tracy S, Chapman NM, Romero J, Ramsingh AI. Genetics of Coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Trends Microbiol. 4, 175-179 (1996).
41. Knowlton KU, Jeon ES, Berkley N et al. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of Coxsackievirus B3. J. Virol. 70, 7811-7818 (1996).
42. Fohlman J, Ilback NG, Friman G, Morein B. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 8, 381-384 (1990).
43. Fohlman J, Pauksen K, Morein B et al. High yield production of an inactivated Coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand. J. Infect. Dis. (Suppl.), 88, 103-108 (1993).
44. See DM, Tilles JG. Occurrence of Coxsackievirus hepatitis in baby rabbits and protection by a formalin-inactivated polyvalent vaccine. Proc. Soc. Exp. Biol. Med. 216, 52-56 (1997).
45. Citan ZM, Tren SM, Ruan KC. A Vaccine to Coxsackievirus Prepzed by High Pressure. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Yue Bao (Shanghai) 33, 128-130 (2001).
46. Kishimoto C, Takada H, Hiraoka Y et al. Protection against murine Coxsackievirus B3 myocarditis by T cell vaccination. J. Mol. Cell Cardiol. 32, 2269-2277 (2000).
47. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468 (1990).
48. Boyer JD, Kim J, Ugen K et al. HIV-1 DNA vaccines and chemokines. Vaccine 17(Suppl.2), S53-S64 (1999).
49. Konishi E, Yamaoka M, Khin Sane W et al. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J. Virol. 73, 5527-5534 (1999).
50. Qiu JT, Song R, Dettenhofer M et al. Evaluation of novel human immunodeficiency virus type 1 gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J. Virol. 73, 9145-9152 (1999).
51. Schirmbeck R, Bohm W, Ando K et al. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 69, 5929-5934 (1995).
52. Henke A, Wagner E, Whitton JL et al. Protection of mice against lethal Coxsackievirus B3 infection by using DNA immunization. J. Virol. 72, 8327-8331 (1998).
53. Sin JI, Sung JH, Suh YS et al. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene. Vaccine 15, 1827-1833 (1997).
54. Toniolo A, Falcone V, Bernasconi C et al. DNA immunization of mice against the VP1 capsid protein of Coxsackievirus B4. Scand. J. Immunol. 56, 448-455 (2002).
55. Pulli T, Roivainen M, Hovi T, Hyypia T. Induction of neutralizing antibodies by synthetic peptides representing the C terminus of Coxsackievirus A9 capsid protein VP1. J. Gen. Virol. 79, 2249-2253 (1998).
56. Zamorano PI, Wigdorovitz A, Perez Filgueira DM et al. Induction of anti foot and mouth disease virus T and B cell responses in cattle immunized with a peptide representing ten amino acids of VP1. Vaccine 16, 558-563 (1998).
57. Henke A, Zell R, Stelmer A. DNA vaccine-mediated immune responses in Coxsackie-virus B3-infected mice. Antitiral. Res. 49, 49-54 (2001).
58. Operschall E, Pavlovic J, Nawrath M, Molling K. Mechanism of protection against influenza A virus by DNA vaccine encoding the hemagglutinin gene. Intervirology 43, 322-330 (2000).
59. Tolley ND, Tsunoda I, Fujinami RS. DNA vaccination against Theiler's murine encephalomyelitis virus leads to alterations in demyelinating disease. J. Virol. 73, 993-1000 (1999).
60. Chapman NM, Ragland A, Leser JS et al. A group B Coxsackievirus/Poliovirus 5′ nontranslated region chimera can act as an vaccine strain in mice. J. Virol. 74, 4047-4056 (2000).
61. Hofling K, Tracy S, Chapman N et al. Expression of an antigenic adenovirus epitope in a group B Coxsackievirus. J. Virol. 74, 4570-4578 (2000).
62. Chapman NM, Kim KS, Tracy S et al. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. J. Virol. 74, 7952-7962 (2000).
63. + T cells. Annu. Rev. Immunol. 12, 635-673 (1994).
64. Horwitz MS, Krahl T, Fine C et al. Protection from lethal Coxsackievirus-induced pancreatitis by expression of γ IFN. J. Virol. 73, 1756-1766 (1999).
65. Horwitz MS, La Cava A, Fine C et al. Pancreatic expression of IFN-γ protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis. Nat. Med. 6, 693-697 (2000).
66. Nishio R, Matsumori A, Shioi T et al. Treatment of experimental viral myocarditis with interleukin-10. Circulation 100, 1102-1108 (1999).
67. Henke A, Zell R, Martin U, Stelzner A. Direct IFN-γ-mediated protection caused by a recombinant Coxsackievirus B3. Virology 315, 335-344 (2003).
68. Henke A, Zell R, Ehrlich G, Stelzner A. Expression of immunoregulatory cytokines by recombinant Coxsackievirus B3 variants confers protection against virus-induced myocarditis. J. Virol. 75, 8187-8194 (2001).
69. Geiger K, Howes E, Gallina et al. Transgenic mice expressing IFN-γ in the retina develop inflammation of the eye and photoreceptor loss. Invest. Ophthalmol. Vis. Sci. 35, 2667-2681 (1994).
70. Horwitz MS, Evans CF, McGavern DB et al. Primary demyelination in transgenic mice expressing IFN-γ. Nat. Med. 3, 1037-1041 (1997).
71. Ramsay AJ, Ruby J, Ramshaw IA. A case for cytokines as effector molecules in the resolution of virus infection. Immunol. Today 14, 155-157 (1993).
72. Gu D, Sarvetnick N. Epithelial cell proliferation and islet neogenesis in IFN-γ transgenic mice. Development 118, 33-46 (1993).
73. Pavlovic J, Schroder A, Blank A et al. Mx proteins: GTPases involved in the interferon-induced antiviral state. Ciba Found Symp. 176, 233-243 (1993).
74. Sen GC, Ransohoff RM. IFN-induced antiviral actions and their regulation. Adv. Virus. Res. 42, 57-102 (1993).
75. Badorff C, Fichtlscherer B, Muelsch A et al. Selective delivery of nitric oxide to a cellular target: a pseudosubstrate-coupled dinitrosyl-iron complex inhibits the enteroviral protease 2A. Miric Oxide 6, 305-312 (2002).
76. Badorff C, Fichdscherer B, Rhoads RE et al. Nitric oxide inhibits dystrophin proteolysis by Coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. Circulation 102, 2276-2281 (2000).
77. Saura M, Zaragoza C, McMillan A et al. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 10, 21-28 (1999).
78. Zell R, Markgraf R, Schmidtke M et al. Nitric oxide donors inhibit the Coxsackievirus B3 proteinases 2A and 3C in vitro and virus production in vivo. Med. Microbiol. Immunol. (2003) (In Press).